Sleep duration and incidence of lung cancer in ageing men

BMC Public Health

Jussi Kauhanen¹  Arja T Erkkilä¹  Tommi Tolmunen²  Soili M Lehto²  Maria K Luojus¹ 

[1] Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 162770211 Kuopio, Finland;University of Eastern Finland, P.O. Box 162770211 Kuopio, Finland

关键词: Lung cancer;    Sleep duration;    Prospective cohort study;   

Others  :  1131741
DOI  :  10.1186/1471-2458-14-295

 received in 2013-10-17, accepted in 2014-03-27,  发布年份 2014

【 摘 要 】

Background

Previous studies have suggested an association between sleep duration and cancer. However, the information on sleep duration regard to risk of lung cancer is scanty.

Methods

Analysed data comprised prospective population-based cohort of 2586 men (aged 42–60 years) from Eastern Finland. Baseline survey and clinical examinations took place 1984–1989, and diagnosed lung cancers were obtained until the end of 2011 through linkage with the Finnish Cancer Registry. Self-reported sleep was categorized as ≤6.5 h, 7–7.5 h, and ≥8 h. Subjects with prior history of cancer or psychotropic medication (hypnotics or sedatives) were excluded from the analyses. Cox proportional hazards models with adjustments for possible confounders were used to examine the association.

Results

Significant association between sleep duration and increased lung cancer risk was observed after adjustments for age, examination years, cumulative smoking history, family cancer history and Human Population Laboratory Depression scale scores (HR 2.12, 95% CI 1.17-3.85 for ≤6.5 h sleep, and HR 1.88, 95% CI 1.09-3.22 for ≥8 h sleep). Associations were even stronger among current smokers (HR 2.23, 95% CI 1.14-4.34 for ≤6.5 h sleep, and HR 2.09, 95% CI 1.14-3.81 for ≥8 h sleep). After further adjustments for alcohol consumption, physical activity, body mass index, marital status, education years, night work, employment status, asthma and chronic bronchitis, the association remained significant both in the whole study population and among smokers. When cumulative smoking history was replaced by current smoking in the adjustments, the increased risk was limited to those who slept <6.5 h.

Conclusions

Sleep duration of less than 7–7.5 hours or more than 7–7.5 hours associates with increased lung cancer risk. The physiological factors underlying the association are complex, and they may relate to melatonin excretion patterns, low-grade inflammation in cancer development process or disruptions in circadian rhythmicity.

【 授权许可】

   
2014 Luojus et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bray F, Ren JS, Masuyer E, Ferlay J: Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013, 1:1133-1145.
• [2]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin : Cancer incidence and mortality worldwide. [http://globocan.iarc.fr webcite]
• [3]Engholm G, Ferlay J, Christensen N, Johannesen TB, Klint Å, Køtlum JE, Milter MC, Ólafsdóttir E, Pukkala E, Storm HH: Cancer incidence, mortality, prevalence and survival in the nordic countries. [http://www.ancr.nu webcite]
• [4]Flaherty KR, Herridge MS: Clinical year in review II: Lung cancer, sleep apnea, interventional pulmonary/pleural disease, cystic fibrosis. Proc Am Thorac Soc 2011, 8:398-403.
• [5]Cassidy A, Myles JP, Liloglou T, Duffy SW, Field JK: Defining high-risk individuals in a population-based molecular-epidemiological study of lung cancer. Int J Oncol 2006, 28:1295-1301.
• [6]Erren TC: Sleep duration and cancer risk: time to use a “sleep-years” index? Cancer Causes Control 2012, 23:1399-1403.
• [7]Sack RL, Auckley D, Auger RR, Carskadon MA, Wright KP Jr, Vitiello MV, Zhdanova IV: Circadian rhythm sleep disorders: Part I, basic principles, shift work and jet lag disorders. An American Academy of sleep medicine review. Sleep 2007, 30:1460-1483.
• [8]Blask DE: Melatonin, sleep disturbance and cancer risk. Sleep Med Rev 2009, 13:257-264.
• [9]Fic M, Podhorska-Okolow M, Dziegiel P, Gebarowska E, Wysocka T, Drag-Zalesinska M, Zabel M: Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line hep-2). In Vivo 2007, 21:513-518.
• [10]Vesnushkin GM, Plotnikova NA, Semenchenko AV, Anisimov VN: Melatonin inhibits urethane-induced carcinogenesis tumors in murine lung. Vopr Onkol 2006, 52:164-168.
• [11]Mazzoccoli G, Tarquini R, Durfort T, Francois JC: Chronodisruption in lung cancer and possible therapeutic approaches. Biomed Pharmacother 2011, 65:500-508.
• [12]Grutsch JF, Wood PA, Du-Quiton J, Reynolds JL, Lis CG, Levin RD, Ann Daehler M, Gupta D, Quiton DF, Hrushesky WJ: Validation of actigraphy to assess circadian organization and sleep quality in patients with advanced lung cancer. J Circadia Rhythms 2011, 18:1-12.
• [13]Du-Quiton J, Wood PA, Burch JB, Grutsch JF, Gupta D, Tyer K, Lis CG, Levin RD, Quiton DF, Reynolds JL, Hrushesky WJ: Actigraphic assessment of daily sleep-activity pattern abnormalities reflects self-assessed depression and anxiety in outpatients with advanced non-small cell lung cancer. Psycho Oncol 2010, 19:180-189.
• [14]Vena C, Parker K, Allen R, Bliwise D, Jain S, Kimble L: Sleep-wake disturbances and quality of life in patients with advanced lung cancer. Oncol Nurs Forum 2006, 1:761-769.
• [15]Miaskowski C, Cooper BA, Dhruva A, Dunn LB, Langford DJ, Cataldo JK, Baggoll CR, Merriman JD, Dodd M, Lee K, West C, Paul SM, Aouizerat BE: Evidence of associations between cytokine genes and subjective reports of sleep disturbance in oncology patients and their family caregivers. PLoS One 2012, 7:e40560.
• [16]von Ruesten A, Weikert C, Fietze I, Boeing H: Association of sleep duration with chronic diseases in the european prospective investigation into cancer and nutrition (EPIC)-potsdam study. PLoS One 2012, 7:e30972.
• [17]Kakizaki M, Inoue K, Kuriyama S, Sone T, Matsuda-Ohmori K, Nakaya N, Fukudo S, Tsuji I: Sleep duration and the risk of prostate cancer: the Ohsaki cohort study. Br J Cancer 2008, 8:176-178.
• [18]Kakizaki M, Kuriyama S, Sone T, Ohmori-Matsuda K, Hozawa A, Nakaya N, Fukudo S, Tsuji I: Sleep duration and the risk of breast cancer: the Ohsaki cohort study. Br J Cancer 2008, 4:1502-1505.
• [19]Verkasalo PK, Lillberg K, Stevens RG, Hublin C, Partinen M, Koskenvuo M, Kaprio J: Sleep duration and breast cancer: a prospective cohort study. Cancer Res 2005, 15:9595-9600.
• [20]Wu AH, Wang R, Koh WP, Stanczyk FZ, Lee HP, Yu MC: Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis 2008, 29:1244-1248.
• [21]Thompson CL, Larkin EK, Patel S, Berger NA, Redline S, Li L: Short duration of sleep increases risk of colorectal adenoma. Cancer 2011, 15:841-847.
• [22]Jiao L, Duan Z, Sangi-Haghpeykar H, Hale L, White DL, El-Serag HB: Sleep duration and incidence of colorectal cancer in postmenopausal women. Br J Cancer 2013, 108:213-221.
• [23]Erren TC, Pape HG, Reiter RJ, Piekarski C: Chronodisruption and cancer. Naturwissenschaften 2008, 95:367-382.
• [24]Salonen JT: Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease risk factor study. Ann Clin Res 1996, 41:541-549.
• [25]Lu Y, Tian N, Yin J, Shi Y, Huang Z: Association between sleep duration and cancer risk: a meta-analysis of prospective cohort studies. PLoS One 2013, 4:e74723.
• [26]Kaplan GA, Roberts RE, Camacho TC, Coyne JC: Psychosocial predictors of depression. prospective evidence from the Human Population Laboratory studies. Am J Epidemiol 1987, 125:206-220.
• [27]Roberts RE: Prevalence of depressive symptoms among Mexican Americans. J Nerv Ment Dis 1981, 169:213-219.
• [28]Roberts RE, O’Keefe SJ: Sex differences in depression re-examined. J Health Soc Behav 1981, 22:394-400.
• [29]Salonen JT, Slater JS, Tuomilehto J, Rauramaa R: Leisure time and occupational physical activity: risk of death from ischemic heart disease. Am J Epidemiol 1988, 127:87-94.
• [30]Kauhanen J, Julkunen J, Salonen JT: Coping with inner feelings and stress: heavy alcohol use in the context of alexithymia. Behav Med 1992, 18:121-126.
• [31]Cappuccio FP, D’Elia L, Strazzullo P, Miller MA: Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep 2010, 33:585-592.
• [32]Lee PN, Forey BA, Coombs KJ: Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer 2012, 12:385. BioMed Central Full Text
• [33]Chaiton MO, Cohen JE, O’Loughlin J, Rehm J: A systematic review of longitudinal studies on the association between depression and smoking in adolescents. BMC Public Health 2009, 22:356.
• [34]Bixler E: Sleep and society: an epidemiological perspective. Sleep Med 2009, 10(Suppl 1):3-6.
• [35]Zhang L, Samet J, Caffo B, Punjabi NM: Cigarette smoking and nocturnal sleep architecture. Am J Epidemiol 2006, 15:529-537.
• [36]Adamkova V, Hubacek JA, Lanska V, Vrablik M, Kralova Lesna I, Suchanek P, Zimmelova P, Veleminsky M: Association between duration of the sleep and body weight. Physiol Res 2009, 58(Suppl 1):27-31.
• [37]Giacosa A, Rondanelli M: Fish oil and treatment of cancer cachexia. Genes Nutr 2008, 3:25-28.
• [38]Savvidis C, Koutsilieris M: Circadian rhythm disruption in cancer biology. Mol Med 2012, 6:1249-1260.
• [39]Bollinger T, Bollinger A, Oster H, Solbach W: Sleep, immunity, and circadian clocks: a mechanistic model. Gerontology 2010, 56:574-580.
• [40]Pandi-Perumal SR, Smits M, Spence W, Srinivasan V, Cardinali DP, Lowe D, Kayumov L: Dim light melatonin onset (DLMO): a tool for the analysis of circadian phase in human sleep and chronobiological disorders. Prog Neuropsychopharmacol Biol Psychiatry 2007, 30:1-11.
• [41]Claustrat B, Brun J, Chazot G: The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005, 9:11-24.
• [42]Tamarkin L, Danforth D, Lichter A, DeMoss E, Cohen M, Chabner B, Lippman M: Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 1982, 28:1003-1005.
• [43]Schernhammer ES, Hankinson SE: Urinary melatonin levels and breast cancer risk. J Nat Cancer Inst 2005, 20:1084-1087.
• [44]Kripke DF, Youngstedt SD, Rex KM, Klauber MR, Elliott JA: Melatonin excretion with affect disorders over age 60. Psychiatry Res 2003, 1:47-54.
• [45]Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ: Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 2010, 17:4462-4481.
• [46]Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Benbrahim-Tallaa L, Cogliano V: Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 2007, 8:1065-1066.
• [47]Sack RL, Auckley D, Auger RR, Carskadon MA, Wright KP Jr, Vitiello MV, Zhdanova IV: Circadian rhythm sleep disorders: Part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of sleep medicine review. Sleep 2007, 30:1484-1501.
• [48]Shi J, Chatterjee N, Rotunno M, Wang Y, Pesatori AC, Consonni D, Li P, Wheeler W, Broderick P, Henrion M, Eisen T, Wang Z, Cuen W, Dong Q, Albanes D, Thun M, Spitz MR, Bertazzi PA, Caporaso NE, Chanock SJ, Amos CI, Houlston RS, Landi MT: Inherited variation at chromosome 12p13.33, including RAD52, influences the risk of squamous cell lung carcinoma. Cancer Discov 2012, 2:131-139.
• [49]Rohleder N, Aringer M, Boentert M: Role of interleukin-6 in stress, sleep, and fatigue. Ann N Y Acad Sci 2012, 1261:88-96.
• [50]Teppo L, Pukkala E, Lehtonen M: Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994, 33:365-369.
• [51]Kripke DF, Langer RD, Elliott JA, Klauber MR, Rex KM: Mortality related to actigraphic long and short sleep. Sleep Med 2011, 12:28-33.
• [52]National Agency for Medicines: Finnish statistics on medicines 2007. [http://www.kela.fi/documents/12099/12170/laaketilasto07_2.pdf webcite]